Impact Of Chronic Kidney Disease On The Pharmacodynamic And Pharmacokinetic Effects Of Ticagrelor In Patients With Diabetes Mellitus And Coronary Artery Disease.

European Heart Journal. Cardiovascular Pharmacotherapy
Francesco FranchiDominick J Angiolillo

Abstract

Patients with diabetes mellitus (DM) and chronic kidney disease (CKD) are at increased risk of atherothrombotic events. Ticagrelor reduces ischaemic events compared to clopidogrel, with the greatest risk reduction in patients with both DM and CKD. How CKD status affects the pharmacodynamic (PD) and pharmacokinetic (PK) profiles of different ticagrelor maintenance dose regimens in patients with DM is unknown. In this randomized, cross-over study, patients with DM on treatment with dual antiplatelet therapy (aspirin and clopidogrel) were stratified according to CKD status and randomized to ticagrelor 90 mg bid or 60 mg bid. PK/PD assessments were performed at baseline, after 7-10 days of ticagrelor (peak and trough), and after 7-10 days of alternative ticagrelor regimen (peak and trough). PK assessments included plasma concentrations of ticagrelor and its major metabolite. PD assessments included VASP-PRI, VerifyNow P2Y12, and LTA.A total of 92 patients with DM (CKD, n = 44; non-CKD, n = 48) were randomized. Levels of platelet reactivity were lower with the 90 mg compared with the 60 mg ticagrelor dose, which was statistically significant in non-CKD but not in CKD patients for most PD measures. There were no significant differenc...Continue Reading

References

Sep 24, 2004·The New England Journal of Medicine·Alan S GoChi-yuan Hsu
Oct 16, 2007·Journal of the American College of Cardiology·Dominick J AngiolilloAntonio Fernandez-Ortiz
Nov 8, 2007·JAMA : the Journal of the American Medical Association·Josef CoreshAndrew S Levey
Sep 1, 2009·The New England Journal of Medicine·Lars WallentinMona Thorsén
Mar 13, 2010·Journal of the American College of Cardiology·Dominick J AngiolilloAntonio Fernandez-Ortiz
Feb 24, 2011·Circulation·José Luis Ferreiro, Dominick J Angiolillo
Oct 1, 2011·Journal of Clinical Pharmacology·Kathleen Butler, Renli Teng
May 31, 2012·Circulation·Davide Capodanno, Dominick J Angiolillo
Nov 13, 2012·Journal of Thrombosis and Thrombolysis·Antonio Tello-MontoliuDominick J Angiolillo
Mar 12, 2013·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Olivier MorelThierry Hannedouche
Mar 22, 2014·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Lesley A InkerHarold I Feldman
Sep 6, 2014·Journal of the American College of Cardiology·Dominick J AngiolilloTheodore A Bass
Oct 8, 2014·Nature Reviews. Cardiology·Francesco Franchi, Dominick J Angiolillo
Feb 25, 2015·JAMA : the Journal of the American Medical Association·Andrew S LeveyLesley A Inker
Mar 17, 2015·The New England Journal of Medicine·Marc P BonacaUNKNOWN PEGASUS-TIMI 54 Steering Committee and Investigators
Mar 12, 2016·Journal of the American College of Cardiology·Robert F StoreyMarc S Sabatine
Oct 28, 2016·Thrombosis and Haemostasis·Lydia R EngwenyuDominick J Angiolillo
Nov 1, 2017·Circulation·Dominick J AngiolilloMatthew J Price
Dec 14, 2018·Journal of the American College of Cardiology·Davide CapodannoDominick J Angiolillo
Aug 5, 2019·JACC. Cardiovascular Interventions·Francesco FranchiDominick J Angiolillo
Dec 22, 2019·Diabetes Care·UNKNOWN American Diabetes Association

❮ Previous
Next ❯

Citations

Aug 28, 2021·Diagnostics·Mădălina Ioana MoisiMircea Ioachim Popescu

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.